Identification

Name
Regramostim
Accession Number
DB05386
Description

Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages. Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. GM-CSF stimulates proliferation, activation and differentiation of macrophages and granulocytes and their progenitors.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Colony-stimulating factor 2 (human clone pCSF-1 protein moiety reduced), glycoform GMC 89-107
  • GM-CSF
  • Regramostim
  • Regramostime
  • Regramostimum
  • rhGm-CSF
External IDs
  • GMC 89-107

Pharmacology

Indication

Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

This drug activates mononuclear phagocytes, promotes migration of epithelial cells, and further regulates cytokine production. In 2 recent placebo-controlled studies involving venous leg ulceration, subcutaneous perilesional injections of recombinant human granulocyte-macrophage colony-stimulating factor were found to be significantly better than placebo in the time to complete wound healing. In other studies, recombinant human granulocyte-macrophage colony-stimulating factor was administered topically to wounds. Several case reports have also demonstrated the use of recombinant human granulocyte-macrophage colony-stimulating factor for postsurgical wounds, chronic leg ulcers of sickle cell anemia patients, and refract and refractory pyoderma gangrenosum.

TargetActionsOrganism
UGranulocyte-macrophage colony-stimulating factor receptor subunit alphaNot AvailableHumans
UGM-CSF receptor alpha subunitNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololRegramostim may increase the bradycardic activities of Acebutolol.
AcetylcholineThe risk or severity of adverse effects can be increased when Regramostim is combined with Acetylcholine.
AclidiniumRegramostim may increase the neuromuscular blocking activities of Aclidinium.
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Regramostim.
AmifampridineThe risk or severity of adverse effects can be increased when Regramostim is combined with Amifampridine.
AmitriptylineThe therapeutic efficacy of Amitriptyline can be decreased when used in combination with Regramostim.
AmobarbitalThe therapeutic efficacy of Amobarbital can be decreased when used in combination with Regramostim.
AmoxapineThe therapeutic efficacy of Amoxapine can be decreased when used in combination with Regramostim.
Anisotropine methylbromideThe therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Regramostim.
AripiprazoleThe therapeutic efficacy of Aripiprazole can be decreased when used in combination with Regramostim.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
KR89Q40F01
CAS number
127757-91-9

References

General References
  1. Sardana R, Dudani AK, Tackaberry E, Alli Z, Porter S, Rowlandson K, Ganz P, Altosaar I: Biologically active human GM-CSF produced in the seeds of transgenic rice plants. Transgenic Res. 2007 Dec;16(6):713-21. Epub 2007 Feb 16. [PubMed:17985214]
  2. Rosas M, Gordon S, Taylor PR: Characterisation of the expression and function of the GM-CSF receptor alpha-chain in mice. Eur J Immunol. 2007 Sep;37(9):2518-28. [PubMed:17694571]
PubChem Substance
347910111

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionMycoses1
4CompletedTreatmentDeep Partial Thickness Burn1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentInfertility2
4RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukemia (AML) / Hepatoblastomas / Malignant Lymphomas / Neuroblastomas / Retinoblastoma1
3CompletedTreatmentAcute Myeloid Leukemia (AML)1
3CompletedTreatmentAdult Patients (Over 55) With Acute Non-Lymphocytic Leukemia1
3CompletedTreatmentFever / Hematologic Diseases / Neoplasms, Breast / Neutropenia / Sepsis1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Multiple Myeloma (MM)1
3CompletedTreatmentLeishmaniasis, Cutaneous1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor activity
Specific Function
Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells.
Gene Name
CSF2RA
Uniprot ID
P15509
Uniprot Name
Granulocyte-macrophage colony-stimulating factor receptor subunit alpha
Molecular Weight
46206.185 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
CSF2RA
Uniprot ID
Q16498
Uniprot Name
GM-CSF receptor alpha subunit
Molecular Weight
3014.39 Da

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Takahashi M, Nikkuni K, Moriyama Y, Shibata A: GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase, and cholesterol. Am J Hematol. 1991 Mar;36(3):213-4. [PubMed:1996559]

Drug created on November 18, 2007 11:24 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates